Evidence map›Paper›PMID 37241136›Full record

SynthesisMedicina (Kaunas, Lithuania)2023

Comparison of the Effects of Metformin and Thiazolidinediones on Bone Metabolism: A Systematic Review and Meta-Analysis.

Ru-Dong Chen, Cong-Wen Yang, Qing-Run Zhu, Yu Li, Hai-Feng Hu, Da-Chuan Wang, Shi-Jie Han

Open access · goldFull text readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Global Publication Trends and Research Hotspots of Diabetes and Osteoporosis.Endocrine, metabolic & immune disorders drug targets · 2025
    Review
  3. Metformin and bone metabolism: unraveling their direct and indirect effects.Therapeutic advances in endocrinology and metabolism · 2025
    Review
  4. Bone Loss in Diabetes Mellitus: Diaporosis.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ru-Dong ChenShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Cong-Wen YangDepartment of Neurosurgery, Weifang Medical University, Weifang 261042, China.
Qing-Run ZhuShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Yu LiShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Hai-Feng HuShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Da-Chuan WangShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Shi-Jie HanShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Shandong First Medical University · CNShandong Provincial Hospital · CNWeifang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesStudies have shown that people with diabetes have a high risk of osteoporosis and fractures. The effect of diabetic medications on bone disease cannot be ignored. This meta-analysis aimed to compare the effects of two types of glucose-lowering drugs, metformin and thiazolidinediones (TZD), on bone mineral density and bone metabolism in patients with diabetes mellitus.

methodsThis systematic review and meta-analysis were prospectively registered on PROSPERO, and the registration number is CRD42022320884. Embase, PubMed, and Cochrane Library databases were searched to identify clinical trials comparing the effects of metformin and thiazolidinediones on bone metabolism in patients with diabetes. The literature was screened by inclusion and exclusion criteria. Two assessors independently assessed the quality of the identified studies and extracted relevant data.

resultsSeven studies involving 1656 patients were finally included. Our results showed that the metformin group had a 2.77% (SMD = 2.77, 95%CI [2.11, 3.43];

Indexed as

Diabetes Mellitus, Type 2MetforminOsteoporosisThiazolidinedionesBone DensityCollagen Type IHumansCollagen Type IMetforminProcollagen Type IThiazolidinedionesbone densitybone turnover markersdiabetesmetforminosteoporosisthiazolidinediones

Identifiers

PMID37241136
PMCPMC10222792
OpenAlexW4378515041

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.